{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T08:46:04Z","timestamp":1785746764684,"version":"3.56.0"},"reference-count":29,"publisher":"Informa UK Limited","issue":"7","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["00430A121"],"award-info":[{"award-number":["00430A121"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["BERING21A0"],"award-info":[{"award-number":["BERING21A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"NIH\/NIDCR training","doi-asserted-by":"publisher","award":["T90-DE02198213"],"award-info":[{"award-number":["T90-DE02198213"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"published-print":{"date-parts":[[2026,7,3]]},"DOI":"10.1080\/17425255.2026.2689048","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T14:52:55Z","timestamp":1781362375000},"page":"561-573","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Effect of concomitant rifampin and clarithromycin on elexacaftor-tezacaftor-ivacaftor using a physiologically based pharmacokinetic (PBPK) modeling approach"],"prefix":"10.1080","volume":"22","author":[{"given":"Madeline","family":"Sanders","sequence":"first","affiliation":[{"name":"University of Southern California","place":["Los Angeles, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunjin","family":"Hong","sequence":"additional","affiliation":[{"name":"Dongguk University-Seoul","place":["Goyang-si, South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manya","family":"Jain","sequence":"additional","affiliation":[{"name":"University of Southern California","place":["Los Angeles, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3744-3310","authenticated-orcid":false,"given":"Paul","family":"Beringer","sequence":"additional","affiliation":[{"name":"University of Southern California","place":["Los Angeles, USA"]},{"name":"USC Anton Yelchin CF Clinic, Keck Medicine of USC","place":["Los Angeles, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"e_1_3_6_3_1","unstructured":"Cystic Fibrosis Foundation. Cystic fibrosis Foundation patient registry 2024 annual data report. 2025 Available from cited 2026 May 5]. Available from: https:\/\/www.cff.org\/Gmedia\/38406\/download"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207983"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201309-310OC"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.01.071"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202108-1986OC"},{"key":"e_1_3_6_9_1","unstructured":"Vertex Pharmaceuticals Incorporated. TRIKAFTA (elexacaftor tezacaftor and ivacaftor tablets; ivacaftor tablets): highlights of prescribing information. 2023. Available from cited 2026 May 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/212273s011 217660s002lbl.pdf"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23971"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2019.09.06"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11236900"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13134"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.03.010"},{"key":"e_1_3_6_15_1","unstructured":"U.S. Food and Drug Administration Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): ivacaftor. 2012 Available from cited 2026 May 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203188Orig1s000ClinPharmR.pdf"},{"key":"e_1_3_6_16_1","unstructured":"U.S. Food and Drug Administration Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): tezacaftor\/ivacaftor. 2017. Available from cited 2026 May 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210491Orig1s000ClinPharmR.pdf"},{"key":"e_1_3_6_17_1","unstructured":"U.S. Food and Drug Administration Center for Drug Evaluation and Research. Multi-discipline review: elexacaftor\/tezacaftor\/ivacaftor. 2019. Available from: cited 2026 May 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212273Orig1s000MultidisciplineR.pdf"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2585"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00099-10"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2021.10.003"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-015-0029-0"},{"issue":"1","key":"e_1_3_6_22_1","first-page":"124","article-title":"Concentration of clarithromycin and 14-R-hydroxy-clarithromycin in plasma of patients with Mycobacterium avium complex infection, before and after the addition of rifampicin","volume":"57","author":"Yamamoto F","year":"2004","unstructured":"Yamamoto F, Harada S, Mitsuyama T, et al. Concentration of clarithromycin and 14-R-hydroxy-clarithromycin in plasma of patients with Mycobacterium avium complex infection, before and after the addition of rifampicin. Jpn J Antibiot. 2004;57(1):124\u2013133.","journal-title":"Jpn J Antibiot"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.04.005"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41030-020-00124-7"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01193-08"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.2174\/1872312812666180328105259"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.577263"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.05.001"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2025.09.002"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.11.015"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab582"}],"container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2026.2689048","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/17425255.2026.2689048","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2026.2689048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T08:04:11Z","timestamp":1785744251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2026.2689048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,3]]}},"alternative-id":["10.1080\/17425255.2026.2689048"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2026.2689048","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}